Douglas Tremblay, MD
Hematology · New York, NYNPI 1972921807
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,701 of the $35,447 with a category attached, or 78.1%. 26 manufacturers reported payments, led by Ipsen Innovation at 28.2% of the total. 2025 is the largest year on record at $14,611, more than ten times the $381 reported in 2019.
Across 89 payments — averaging $398.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$10K
- AbbVie$8K
- GSK$7K
- Geron Corporation$3K
- Pharmaessentia USA Corporation$3K
- Novartis$771
- plus $3K from 20 others
Across 12 payments — averaging $16,321 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$125K
- Sobi, Inc$70K
What the payments were for
- Consulting fees$27,70178%
- Speaking & faculty fees$2,9008%
- Travel & lodging$8943%
- Food & beverage$3,85711%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 4 | $10,010 |
| AbbVie | 9 | $8,154 |
| GSK | 14 | $7,159 |
| Geron Corporation | 1 | $3,200 |
| Pharmaessentia USA Corporation | 1 | $2,900 |
| Novartis | 6 | $771 |
| Blueprint Medicines Corporation | 12 | $581 |
| Sobi, Inc | 3 | $376 |
| Daiichi Sankyo Inc. | 5 | $348 |
| Gilead | 5 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $207 |
| Sanofi | 2 | $191 |
| Amgen | 2 | $156 |
| Bristol Myers Squibb | 5 | $150 |
| Genentech USA, Inc. | 1 | $147 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| AstraZeneca | 1 | $119 |
| CTI Biopharma Corp. | 2 | $113 |
| Stemline Therapeutics Inc. | 1 | $103 |
| Seagen Inc. | 1 | $95 |
| Incyte Corporation | 3 | $70 |
| Rigel Pharmaceuticals, Inc. | 1 | $40 |
| Servier Pharmaceuticals LLC | 2 | $38 |
| Syndax Pharmaceuticals, Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Taiho Oncology, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,447 in reported general payments places this provider in the 85th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PegasysPeginterferon Alfa-2a | 13 | $58,197 |
| Posaconazole | 25 | $24,987 |
| Atovaquone | 17 | $16,833 |
| Imatinib Mesylate | 12 | $8,663 |
| Acyclovir | 38 | $528 |
| Hydroxyurea | 40 | $519 |
| Levofloxacin | 29 | $156 |
Paid to pharmacies, not to this prescriber.
Other hematology in New York
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.